MPOX感染の予防のためにHIVとともに生きている成人におけるMVA-BNの免疫原性および安全試験、Kinshasa、DRC (Mbote-HIVAX)
MPOX生物学、結果、伝播、疫学プロジェクト - MPOX暴露試験に対するHIV予防接種とワクチン接種
This is an open-label, phase 2, immunogenicity and safety trial of the MVA-BN vaccine for the prevention of mpox in adults living with HIV with different level of CD4 counts in Kinshasa, DRC.
The study team aims to investigate whether the administration of 2 standard subcutaneous doses of the Modified Vaccinia Ankara of Bavarian Nordic (MVA-BN) vaccine given 28 days apart, is immunogenic and safe when administered to People Living with HIV (PLHIV) with different levels of CD4 counts in the Democratic Republic of the Congo (DRC).
Enrollment will be stratified according to three different subgroups based on CD4 counts assessed during visit 1A: <200 cells/µL; 200 to 499 cells/µL; ≥ 500 cells/µL. A total of 600 participants will be included in the trial, with 200 participants per subgroup.
All participants will be invited to 6 trial visits over a period of 7 months.
This study will take place in cooperation with the National Programme for the Fight against AIDS (PNLS), the 'Programme Elargi de Vaccination (PEV)' and the 'Institut National de Santé Publique (INSP)'. As part of the response to the current mpox epidemic in DRC, a large cohort of about 10,000 individuals living in Kinshasa will be vaccinated in this program. Vaccination will take place in the Centre Hospitalier Kabinda (CHK) and the Pakadjuma Health Centre. All people living with HIV (PLHIV) with the intention to be vaccinated in the CHK, will be asked for their willingness to participate in the MBOTE-HIVAX clinical trial until the sample size of 600 participants needed for this clinical trial is reached.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
-
Kinshasa、コンゴ民主共和国
- Centre Hospitalier Kabinda
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 years and ≤ 45 years at time of informed consent
- Able and willing to provide written informed consent
- Infected with HIV and receiving combination antiretroviral therapy (ART) for ≥ 8 weeks prior to study entry and vaccination
- Preparedness to follow the study schedule
- Willingness to use contraception for 1 month after each vaccination (only for women of childbearing potential)
Exclusion Criteria:
- A known history of mpox and/or smallpox
- A known history of vaccination with 1st, 2nd or 3rd generation smallpox vaccines, or vaccine platforms that contain MVA as a vector
- Planned MVA-based vaccination (other than study vaccination) during the trial
- Close contact to a confirmed mpox case in the 3 weeks prior to study enrollment
- Uncontrolled severe infection or other condition requiring hospitalization
- Pregnancy
- History of anaphylaxis or severe allergic reaction to any vaccine or known allergy to one of the components of the study vaccine
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:CD4 <200
Participants in this arm are stratified in the group with participants with a CD4 level below 200cells/µL. |
All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28. |
|
実験的:CD4 200-499
Participants in this arm are stratified in the group with participants with a CD4 level between 200 and 499 cells/µL. |
All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28. |
|
実験的:CD4 >= 500
Participants in this arm are stratified in the group with participants with a CD4 level of 500cells/µL or more. |
All participants will be vaccinated on day 0 with the MVA-BN vaccine followed by a second injection on day 28. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Seroconversion rates for monkeypox virus (MPXV) neutralizing antibodies
時間枠:2 weeks after the last vaccine dose
|
Seroconversion two weeks after administration of two standard doses of MVA-BN, defined as either the appearance of an MPXV neutralizing antibody titre (NT50) greater than or equal to the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline |
2 weeks after the last vaccine dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and reactogenicity of the MVA-BN vaccine in PLHIV
時間枠:Up to day 14 and until end of participation
|
Solicited local AEs (pain, redness, swelling, induration, and itch at the injection site) and systemic AEs (generalized myalgia, headache, fatigue, nausea and/or vomiting, chills and/or fever (≥ 38.0°C)) up to day 14 post vaccination Unsolicited AEs up to day 14 post vaccination SAEs until the end of participation |
Up to day 14 and until end of participation
|
|
Seroconversion rates for vaccinia virus (VACV) neutralizing antibodies
時間枠:2 weeks after last vaccine dose
|
Seroconversion two weeks after administration of two standard doses of MVA-BN, defined as either the appearance of an VACV neutralizing antibody titre (NT50) greater than or equal to the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline. |
2 weeks after last vaccine dose
|
|
Waning of MPXV neutralizing antibodies in PLHIV
時間枠:On day 14 and month 6
|
The ratio between neutralizing antibody titre against MPXV at 6 months (D28 + 6M) versus 14 days (D28 + 14 days) after administration of two standard doses of MVA-BN. |
On day 14 and month 6
|
|
Waning of VACV neutralizing antibodies in PLHIV
時間枠:On day 14 and month 6
|
The ratio between neutralizing antibody titre against VACV at 6 months (D28 + 6M) versus 14 days (D28 + 14 days) after administration of two standard doses of MVA-BN. |
On day 14 and month 6
|
|
Seroconversion rates and IgG antibody titre dynamics against MPXV and VACV antigens in serum
時間枠:day 0 (prior to first dose), Day14, Day 28, Day 28+14 days, Day 28+6Months
|
The absolute IgG antibody titre against the following antigens: A35R, H3L, B2R, A5L, A27L, B6R, E8L and A29L from mpox, and A33R and B5 from vaccinia virus at D14, D28 (second dose), D28+14d, D28+6M after administration of two standard doses of MVA-BN, be defined as either the appearance of Median Fluorescent Values (MFI) greater than the detection limit for initially seronegative participants or more than doubling of the antibody titre compared to baseline for participants seropositive at baseline. |
day 0 (prior to first dose), Day14, Day 28, Day 28+14 days, Day 28+6Months
|
協力者と研究者
捜査官
- 主任研究者:Laurens Liesenborghs, MD、Institute of Tropical Medicine
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Mbote-HIVAX
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。